Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Evicel Market Expected To Reach $ Billion By 2030 At % CAGR
The historical expansion stemmed from elevated risks of intraoperative blood loss, constraints associated with mechanical methods for stopping bleeding, the widespread use of plasma-derived preparations, a rise in the number of intricate surgical procedures, and an intensified emphasis on ensuring patient safety.
The expansion during the forecast period is driven by a rise in minimally invasive procedures, higher numbers of surgeries performed, a growing network of specialty clinics, advancements in surgical biomaterials, and a stronger emphasis on improving surgical efficiency. Key developments shaping this period involve the growing application of fibrin sealants during operations, an increased need for hemostatic agents that are biocompatible, more frequent cardiovascular and liver surgeries, a preference for sealants derived from human plasma, and the broadening scope of sophisticated surgical techniques.
Download A Free Sample Report For Comprehensive Market Insights:
Evicel Market Expansion Drivers: What Is Shaping Future Growth?
A growing number of bleeding disorders is anticipated to drive expansion in the evicel market. These disorders involve the blood’s inability to clot correctly, resulting in excessive or prolonged bleeding after injuries or surgeries. This increase stems from factors like a higher incidence of genetic conditions such as hemophilia, lifestyle issues including poor diet and obesity, and the rising prevalence of chronic diseases like liver disorders that impair clotting. Evicel serves as a fibrin sealant in blood disorders, helping achieve hemostasis during surgeries, particularly for patients with coagulation issues such as hemophilia or other clotting deficiencies. For example, in May 2025, Pfizer Inc., a US-based biopharmaceutical firm, reported that the UK’s hemophilia A and B patient population surpassed 11,800 individuals in the 2023/2024 period. Consequently, the rising prevalence of bleeding disorders is set to fuel growth in the evicel market.
The increasing prevalence of chronic conditions is expected to stimulate growth in the evicel market. Chronic conditions, such as diabetes and heart disease, are long-term illnesses lasting a year or more that require ongoing care or limit daily activities. Their rise is driven by aging populations, unhealthy lifestyles, environmental factors, and improved diagnostic capabilities, highlighting both lifestyle and systemic influences. Evicel is frequently applied as a fibrin sealant to manage bleeding during surgeries, especially in patients with chronic diseases that could compromise wound healing or coagulation. This application aids in achieving hemostasis and reducing surgical complications in such patients. For instance, in March 2024, the UK-based Office for Health Improvement & Disparities noted that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes rose by 22%, and for type 2 diabetes by 21%, while HbA1c target achievement reached 37.9%, the highest ever recorded. Thus, the growing prevalence of chronic conditions is driving the evicel market forward.
A rising demand for aesthetic surgeries is projected to boost the evicel market. Aesthetic surgeries encompass non-invasive or minimally invasive treatments aimed at enhancing physical appearance, improving skin texture, and reducing aging signs like wrinkles, fine lines, and sagging skin. This demand is fueled by factors such as increasing incomes, aging populations, social media influence, and advancements in cosmetic technology. Evicel is employed in aesthetic surgeries to improve wound closure and minimize postoperative complications, ensuring reduced scarring and better healing, which aligns with the precision required in cosmetic procedures. For example, in June 2024, the International Society of Aesthetic Plastic Surgery, a US-based professional organization, reported that total surgical and non-surgical procedures increased by 3.4% in 2023, reaching 34.9 million. Face and head procedures experienced particularly strong growth, exceeding 6.5 million cases and representing a 19.6% year-over-year rise. Hence, the growing demand for aesthetic surgeries is fueling the evicel market’s expansion.
Evicel Market Segment Landscape: Which Areas Lead Market Development?
The evicel market covered in this report is segmented –
1) By Type of Surgery: Orthopedic Surgeries, Cardiac Surgeries, General Surgeries, Liver Surgeries, Gynecological Surgeries
2) By Distribution Channel: Hospital Pharmacies, Surgical Supply Distributors, Outpatient Surgery Centers
3) By End-User: Hospitals, Specialty Clinics, Other End-Users
Evicel Market Industry Leaders And Market Competition
Major companies operating in the evicel market are Johnson & Johnson (Omrix Biopharmaceuticals Ltd)
Access The Complete Evicel Market Report:
Evicel Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the evicel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the evicel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model